ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - ContraFect (NASDAQ:CFRX)

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement

YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - ContraFect (NASDAQ:CFRX)

YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to …

Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement

Toronto, Ontario--(Newsfile Corp. - February 27, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the "LIFE Offering"), resu…